Many of you have had questions about the pathway that led to the FDA approval of Imbruvica for WM. I wanted to share with you the attached video of Dr Treon’s interview on this historic approval which I hope… Continue reading
Featuring information on:
Attached please find our March 2014 published manuscript: “Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance“.
The high prevalence of MYD88 L265P in lymphoplasmacytic cells from bone… Continue reading
In the attached report which was just published online in the journal BLOOD, we show how these mutations impact disease presentation and overall survival in WM. CXCR4 is a gene that makes a protein that directs cells to the… Continue reading
” The genomic landscape of Waldenstrom’s Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphoma genesis.:
NEW ORLEANS— In nearly one-third of patients with Waldenstrom’s Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene… Continue reading
” The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling. evading growth suppressors, resisting… Continue reading